Addressing Critical Unmet Need
In advanced solid tumors, metastatic disease remains the leading cause of cancer mortality, and few therapies specifically target metastatic disease. Existing treatments rarely address the intricate interactions between tumor cells and their metastatic niches.
Limited Options
Few targeted therapies specifically address metastases.
Poor Outcomes
Median survival remains limited with current standard of care.
Complex Biology
Tumor microenvironment interactions require innovative approaches.
Our Approach
We leverage AAV-based gene delivery to precisely target and modulate the tumor microenvironment in metastatic sites, disrupting the pathways that enable metastatic progression.
AAV Vector Delivery
Engineered adeno-associated virus vectors designed for precise therapeutic gene delivery at metastatic sites.
Microenvironment Modulation
Target key pathways that influence
tumor-organ ecosystem interactions and metastatic colonization.
One-Time Treatment
Single administration designed to provide durable therapeutic benefit with improved patient convenience and compliance.
First Indication: Breast Cancer Liver Metastasis.
Targeting the critical unmet need in liver-dominant metastatic breast cancer with a one-time, disease-modifying gene therapy.
~50%
of metastatic breast cancer patients develop liver metastases.
<3 Years
median survival once liver metastases are diagnosed.
Zero
approved therapies targeting the tumor-liver microenvironment.
Our Solution: IAT-S2
IAT-S2 is an AAV8-based gene therapy designed to modulate the liver microenvironment, making it hostile to cancer cells. By delivering a therapeutic transgene directly to the liver, we aim to prevent metastatic colonization and inhibit the growth of established tumors.
Indication:
Liver-dominant metastatic breast cancer with liver metastases
Mechanism of Action:
Modulates key pathways in the liver to create an anti-tumorigenic environment.
One-Time Dosing:
Single intravenous administration
High Prevalence:
~15,000 patients annually
The Science Behind Our Platform
InterAct's proprietary platform InterAct Print pinpoints cancer targets and powers anti-metastasis therapies to save lives.
Hypothesis
Cancer cells metastasize by killing neighboring liver cells to create space.
Screening
Gene candidates identified using patented computational methods.
Results
Target gene meets criteria to provide competitive advantage against metastatic cancer cells.
Focused on What Ultimately Kills
90% of cancer deaths caused by metastasis.
No approved therapies targeting metastatic spread.
Breaking the Legacy Gene Therapy Model
Expand beyond ultra-rare indications.
Lower dosing for cost & safety.
Below-traditional pricing.
Platform Potential with Immediate Impact
Lead program: breast cancer liver metastases.
Platform expandable to metastases in multiple cancers.
Platform Strategy
Our platform powers anti-metastasis therapies designed to save lives through innovative approaches
Platform Strategy
Our platform powers anti-metastasis therapies designed to save lives through innovative approaches
Focused on What Ultimately Kills
90% of cancer deaths caused by metastasis.
No approved therapies targeting metastatic spread.
Platform Potential with Immediate Impact
Lead program:
breast cancer liver metastases.
Platform expandable to metastases in multiple cancers.
Breaking the Legacy Gene Therapy Model
Expand beyond ultra-rare indications.
Lower dosing for cost & safety.
Below-traditional pricing.
Unlocking the Profitability of AAVs Through Oncology
Moving beyond traditional rare disease applications to create scalable, impactful gene therapies
Challenged Current Paradigm
Rare Disease
Disruptive Oppurtunity
Solid Disease
Ultra-rare,
monogenic disorders
<100-10,000 globally
per indication
~$1M-$4M per treatment
One gene, one vector,
one patient
Refractory/metastatic
cancers, MRD
>100,000 globally
(across cancers)
~$200k-$500k per treatment
One platform, many cancers,
scalable host reprogramming
Our Team & Advisors
A dedicated group of leaders and experts committed to advancing gene therapy for cancer treatment.
Co-founders
Dan Hargrove, JD LLM
CEO, Co-founder
Isaac Chan, MD, PhD
Co-founder
Board of Advisors
Steve Hahn, MD
Former Commissioner of the FDA
David Hong, MD
Deputy Chair, Investigational Therapeutics, MD Anderson
Donald McDonnell, PhD
Associate Director of Translational Research at the Duke Cancer Institute
Kim Rathmell, MD, PhD
Former Director of the
National Cancer Institute
Interested in Learning More?
Connect with our team to discuss partnerships, investment opportunities, or learn more about our innovative gene therapy approach.